Smartphone-Guided Paced Breathing and Aerobic Exercise for Essential Hypertension

Hypertension is a major risk factor for cardiovascular disease and is associated with reduced functional capacity and impaired quality of life. Non-pharmacological interventions, including aerobic exercise and paced breathing, may improve blood pressure control by enhancing cardiovascular and autonomic function. This randomized controlled trial will evaluate whether combining smartphone-guided paced breathing with aerobic exercise provides greater benefits than either intervention alone in adults with essential hypertension. Seventy-five participants will be randomly assigned to one of three groups: (1) smartphone-guided paced breathing combined with aerobic exercise, (2) aerobic exercise alone, or (3) smartphone-guided paced breathing alone. The intervention will last 12 weeks. The primary outcome measures are systolic and diastolic blood pressure. Secondary outcome measures include heart rate, functional capacity assessed by the 6-Minute Walk Test, and health-related quality of life assessed using the Short Form-12 (SF-12) questionnaire. The findings of this study may help identify an effective, accessible, and low-cost non-pharmacological strategy for improving cardiovascular health and quality of life in patients with essential hypertension.

Inclusion Criteria: Adults aged 40-50 years. Both males and females. Clinically diagnosed with essential (primary) hypertension confirmed by a physician. Stage 1-2 hypertension (SBP 130-160 mmHg and/or DBP 80-100 mmHg) based on standardized clinical measurement. Duration of diagnosed hypertension between 6 months and 5 years. Stable on antihypertensive medication for at least 4 weeks prior to enrollment, with no planned medication changes. Medically stable and cleared for participation in moderate-intensity exercise. Able to understand instructions and independently perform smartphone-guided breathing exercises. Willing to participate and provide written informed consent. Exclusion Criteria: Secondary hypertension (e.g., renal, endocrine, or medication-induced hypertension). Severe or uncontrolled hypertension (SBP \>180 mmHg and/or DBP \>110 mmHg). History of major cardiovascular events (e.g., myocardial infarction within the past 6 months, unstable angina, uncontrolled arrhythmias, or decompensated heart failure). Chronic respiratory diseases affecting exercise tolerance (e.g., chronic obstructive pulmonary disease \[COPD\] or severe asthma). Neurological, musculoskeletal, or orthopedic conditions that limit safe participation in walking or exercise training. Cognitive impairment or psychiatric disorders that affect comprehension or adherence to the study protocol. Participation in a structured exercise or pulmonary rehabilitation program within the previous 3 months. Heavy smoking. Pregnancy or lactation. Contraindications to exercise testing or training according to the American College of Sports Medicine (ACSM) guidelines. Anticipated changes in antihypertensive medication during the study period.